Journal
MOLECULES
Volume 26, Issue 7, Pages -Publisher
MDPI
DOI: 10.3390/molecules26071981
Keywords
aurora kinase B (AURKB); cancer; AURKB regulation; AURKB inhibitors; therapy related drug resistance; combination therapy
Funding
- Innovative Young Biotechnologist Award, Department of Biotechnology, Govt. of India [BT/09/IYBA/2015/10]
- Centre of Excellence grant, Department of Biotechnology, Govt. of India [BT/PR32404/MED/30/2136/2019]
- Hyderabad Eye Research Foundation, LV Prasad Eye Institute, India
Ask authors/readers for more resources
AURKB plays a critical role in tumor development, therapy-related drug resistance, and its inhibition as a potential therapeutic strategy for cancer. Its dysregulation is associated with malignant growth of tumors.
Aurora kinase B (AURKB) is a mitotic serine/threonine protein kinase that belongs to the aurora kinase family along with aurora kinase A (AURKA) and aurora kinase C (AURKC). AURKB is a member of the chromosomal passenger protein complex and plays a role in cell cycle progression. Deregulation of AURKB is observed in several tumors and its overexpression is frequently linked to tumor cell invasion, metastasis and drug resistance. AURKB has emerged as an attractive drug target leading to the development of small molecule inhibitors. This review summarizes recent findings pertaining to the role of AURKB in tumor development, therapy related drug resistance, and its inhibition as a potential therapeutic strategy for cancer. We discuss AURKB inhibitors that are in preclinical and clinical development and combination studies of AURKB inhibition with other therapeutic strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
